Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Urogen Pharma Ltd (NQ: URGN ) 14.16 -0.29 (-2.01%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Urogen Pharma Ltd < Previous 1 2 3 4 5 6 7 Next > Why Shares of UroGen Pharma Jumped Friday July 28, 2023 The company released positive top-line results for two studies for a bladder cancer treatment. Via The Motley Fool Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet July 28, 2023 Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... Via Benzinga Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session July 28, 2023 U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga Why UroGen Pharma Stock Is Gaining Today? July 27, 2023 UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients... Via Benzinga UroGen Pharma Ltd. (NASDAQ: URGN) Near the Top of Equities by Percentage Gain on 7/27 July 27, 2023 Via Investor Brand Network Recap: UroGen Pharma Q1 Earnings May 11, 2023 Via Benzinga UroGen Pharma Earnings Preview March 15, 2023 Via Benzinga UroGen Pharma's Return On Capital Employed Overview December 20, 2022 Via Benzinga UroGen Announces $120 Million Private Placement of Ordinary Shares July 27, 2023 From UroGen Pharma Ltd. Via Business Wire UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials July 27, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors July 25, 2023 From UroGen Pharma Ltd. Via Business Wire Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation July 10, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Host UGN-102 Data Event on July 27, 2023 July 06, 2023 From UroGen Pharma Ltd. Via Business Wire Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration June 20, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 09, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Present at Upcoming Investor Conferences June 02, 2023 From UroGen Pharma Ltd. Via Business Wire Earnings Scheduled For May 11, 2023 May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... Via Benzinga UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments May 11, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023 May 04, 2023 From UroGen Pharma Ltd. Via Business Wire First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation May 01, 2023 From UroGen Pharma Ltd. Via Business Wire New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis April 30, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Present at H.C. Wainwright BioConnect Conference April 25, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments March 16, 2023 From UroGen Pharma Ltd. Via Business Wire Earnings Scheduled For March 16, 2023 March 16, 2023 Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million. Via Benzinga UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023 March 09, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 06, 2023 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Present at Upcoming Investor Conferences March 01, 2023 From UroGen Pharma Ltd. Via Business Wire Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer February 15, 2023 From UroGen Pharma Ltd. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023 February 08, 2023 Via Benzinga Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer January 11, 2023 From UroGen Pharma Ltd. Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.